Pharma firms are expanding beyond small molecules into fusion proteins, ADCs, oligonucleotides, radioligand, and cell/gene therapies—pursuing more precise, potent treatments for neuro, cardiovascular disease, and otherwise difficult cancers
Radioligand therapies combine radioactive isotopes with targeting ligands. Approved examples like Lutetera treat neuroendocrine tumors, and AstraZeneca is working on candidates for resistant prostate cancer.
By adding fusion proteins, ADCs, and oligonucleotides to pipelines, pharma companies reduce reliance on small molecules, spread risk, accelerate innovation, and address unmet medical needs.
PharmaX Next 2026 will spotlight these modalities, with sessions on regulatory harmonization, manufacturing scale-up, AI‐driven discovery, and precision medicine—empowering the next generation of therapies.